资讯
内科
心血管
肿瘤
内分泌
普通内科
消化
呼吸
神经科
传染科
精神心理
肾内科
风湿免疫
血液科
老年医学
外科
头颈外科
胃肠外科
血管外科
肝胆胰外
骨科
普通外科
胸心外科
神经外科
泌尿外科
烧伤科
整形美容
麻醉疼痛
专科科室
罕见病
康复医学
药械
儿科
耳鼻咽喉
口腔科
眼科
政策人文
营养全科
预防公卫
妇产科
中医科
急重症
皮肤性病
影像放射
转化医学
检验病理
护理
热点
临床研究
研究设计
人工智能
智慧医疗
论文基金
医学科普
药物经济
医生集团
职业安全
患者招募
医学科研
公司产业
医学英语
MedSci动态
指南
按科室浏览
肿瘤科
心血管
传染科
妇产科
神经科
儿科
呼吸
内分泌科
血液科
消化
更多科室
工具
临床工具
临床指南
医学计算与公式
ICD-10/ICD-11疾病编码
医迅达
直播
话题
公开课
精品课
科研工具
期刊数据库查询
期刊智能选择
全球基金查询
文献查询
SCI写作宝典
生物医药大词典
其他工具
下载App使用方便更快捷
Medsci 梅斯搜索
公开课
精品课
服务
科研数智化
直播,公开课与精品课
科研加速器
研究者发起的临床研究(IIS)支持
真实世界研究解决方案
药物经济学
医保准入事务
研究方案设计
数据库建立与管理
药物警戒(PV)
真实世界研究执行
数据统计分析
数字化学术传播解决方案
多渠道营销(MCM)
产品医学策略
学术传播(APO)
其它
积分商城
FAQS
map
#丙肝新药#
28篇内容 | 1330人围观
关注话题
话题活跃用户
#
插入话题
插入图片
评论
最新
最热
GetTopicDetailResponse(id=3fac20931ac, topicName=丙肝新药, introduction=丙肝新药, content=null, image=null, comments=28, allHits=1330, url=https://h5.medsci.cn/topic?id=20931, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=25233, tagList=[TagDto(tagId=25233, tagName=丙肝新药)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1665256, encodeId=606816652561b, content=<a href='/topic/show?id=3fac20931ac' target=_blank style='color:#2F92EE;'>#丙肝新药#</a>, objectTitle=【深度解读】医保谈判谁是很大赢家?PD-1谈判结果爆冷,进口丙肝新药平均降价85%!, objectType=article, longId=183748, objectId=8800183e48bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8800183e48bf, replyNumber=0, likeNumber=91, createdTime=2020-05-01, rootId=0, userName=ms24272190615788285182, userId=67e225929577, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8800183e48bf, moduleTitle=【深度解读】医保谈判谁是很大赢家?PD-1谈判结果爆冷,进口丙肝新药平均降价85%!, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8800183e48bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1665255, encodeId=3b511665255cf, content=<a href='/topic/show?id=3fac20931ac' target=_blank style='color:#2F92EE;'>#丙肝新药#</a>, objectTitle=知名肝病专家王宇明:丙肝新药应尽快纳入医保, objectType=article, longId=154030, objectId=ff3215403079, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff3215403079, replyNumber=0, likeNumber=55, createdTime=2019-10-10, rootId=0, userName=ms24272190615788285182, userId=67e225929577, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff3215403079, moduleTitle=知名肝病专家王宇明:丙肝新药应尽快纳入医保, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ff3215403079)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1665254, encodeId=cf72166525495, content=<a href='/topic/show?id=3fac20931ac' target=_blank style='color:#2F92EE;'>#丙肝新药#</a>, objectTitle=国家卫健委调整基本药物目录,丙肝新药“丙通沙”将被纳入, objectType=article, longId=148323, objectId=1c2a148323c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c2a148323c1, replyNumber=0, likeNumber=66, createdTime=2018-09-09, rootId=0, userName=ms24272190615788285182, userId=67e225929577, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c2a148323c1, moduleTitle=国家卫健委调整基本药物目录,丙肝新药“丙通沙”将被纳入, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1c2a148323c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1665251, encodeId=fd8916652514d, content=<a href='/topic/show?id=3fac20931ac' target=_blank style='color:#2F92EE;'>#丙肝新药#</a>, objectTitle=治疗仅需8周!丙肝新药获批, objectType=article, longId=135704, objectId=244f135e04f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=244f135e04f0, replyNumber=0, likeNumber=69, createdTime=2019-02-07, rootId=0, userName=ms24272190615788285182, userId=67e225929577, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=244f135e04f0, moduleTitle=治疗仅需8周!丙肝新药获批, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=244f135e04f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1665252, encodeId=9ff616652527d, content=<a href='/topic/show?id=3fac20931ac' target=_blank style='color:#2F92EE;'>#丙肝新药#</a>, objectTitle=祝贺!默沙东重磅丙肝新药择必达®在中国获批, objectType=article, longId=137653, objectId=71fa13e6531f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=71fa13e6531f, replyNumber=0, likeNumber=58, createdTime=2018-07-19, rootId=0, userName=ms24272190615788285182, userId=67e225929577, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=71fa13e6531f, moduleTitle=祝贺!默沙东重磅丙肝新药择必达®在中国获批, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=71fa13e6531f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1665249, encodeId=7f12166524950, content=<a href='/topic/show?id=3fac20931ac' target=_blank style='color:#2F92EE;'>#丙肝新药#</a>, objectTitle=优先审评审批助力丙肝新药加快上市, objectType=article, longId=114106, objectId=8b601141060e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b601141060e, replyNumber=0, likeNumber=77, createdTime=2018-03-18, rootId=0, userName=ms24272190615788285182, userId=67e225929577, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b601141060e, moduleTitle=优先审评审批助力丙肝新药加快上市, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8b601141060e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1665253, encodeId=b0f416652534d, content=<a href='/topic/show?id=3fac20931ac' target=_blank style='color:#2F92EE;'>#丙肝新药#</a>, objectTitle=又有丙肝新药在国内获批上市了!, objectType=article, longId=138237, objectId=275d13823e9b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=275d13823e9b, replyNumber=0, likeNumber=64, createdTime=2018-08-12, rootId=0, userName=ms24272190615788285182, userId=67e225929577, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=275d13823e9b, moduleTitle=又有丙肝新药在国内获批上市了!, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=275d13823e9b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1665250, encodeId=df551665250d6, content=<a href='/topic/show?id=3fac20931ac' target=_blank style='color:#2F92EE;'>#丙肝新药#</a>, objectTitle=3款重磅丙肝新药中国上市!, objectType=article, longId=116639, objectId=642f116639ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=642f116639ff, replyNumber=0, likeNumber=66, createdTime=2018-07-09, rootId=0, userName=ms24272190615788285182, userId=67e225929577, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=642f116639ff, moduleTitle=3款重磅丙肝新药中国上市!, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=642f116639ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1665248, encodeId=e8ac1665248c4, content=<a href='/topic/show?id=3fac20931ac' target=_blank style='color:#2F92EE;'>#丙肝新药#</a>, objectTitle=4篇文章引发争议,丙肝新药或增加肝癌风险?, objectType=article, longId=79788, objectId=311be97885d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=311be97885d, replyNumber=0, likeNumber=71, createdTime=2016-12-16, rootId=0, userName=ms24272190615788285182, userId=67e225929577, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=311be97885d, moduleTitle=4篇文章引发争议,丙肝新药或增加肝癌风险?, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=311be97885d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1665247, encodeId=000d166524e25, content=<a href='/topic/show?id=3fac20931ac' target=_blank style='color:#2F92EE;'>#丙肝新药#</a>, objectTitle=FDA发布新指南:丙肝新药研发须开展“头对头”研究, objectType=article, longId=67779, objectId=18d36e7796c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18d36e7796c, replyNumber=0, likeNumber=61, createdTime=2016-11-22, rootId=0, userName=ms24272190615788285182, userId=67e225929577, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18d36e7796c, moduleTitle=FDA发布新指南:丙肝新药研发须开展“头对头”研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=18d36e7796c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1665244, encodeId=7b081665244c0, content=<a href='/topic/show?id=3fac20931ac' target=_blank style='color:#2F92EE;'>#丙肝新药#</a>, objectTitle=WHO更新基药目录 增抗丙肝新药等, objectType=article, longId=50736, objectId=049d50e369c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=049d50e369c, replyNumber=0, likeNumber=88, createdTime=2015-11-04, rootId=0, userName=ms24272190615788285182, userId=67e225929577, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=049d50e369c, moduleTitle=WHO更新基药目录 增抗丙肝新药等, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=049d50e369c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1665245, encodeId=02f8166524555, content=<a href='/topic/show?id=3fac20931ac' target=_blank style='color:#2F92EE;'>#丙肝新药#</a>, objectTitle=3型丙肝福音!百时美丙肝新药Daklinza获FDA批准, objectType=article, longId=53837, objectId=6d795383eb4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d795383eb4, replyNumber=0, likeNumber=66, createdTime=2016-02-23, rootId=0, userName=ms24272190615788285182, userId=67e225929577, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d795383eb4, moduleTitle=3型丙肝福音!百时美丙肝新药Daklinza获FDA批准, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6d795383eb4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1665246, encodeId=3ec1166524655, content=<a href='/topic/show?id=3fac20931ac' target=_blank style='color:#2F92EE;'>#丙肝新药#</a>, objectTitle=AASLD 2015:丙肝新药Daklinza治疗晚期肝纤维化3型丙肝治愈率达100%, objectType=article, longId=59142, objectId=6c435914280, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c435914280, replyNumber=0, likeNumber=67, createdTime=2016-10-16, rootId=0, userName=ms24272190615788285182, userId=67e225929577, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c435914280, moduleTitle=AASLD 2015:丙肝新药Daklinza治疗晚期肝纤维化3型丙肝治愈率达100%, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6c435914280)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1665243, encodeId=8d1d166524352, content=<a href='/topic/show?id=3fac20931ac' target=_blank style='color:#2F92EE;'>#丙肝新药#</a>, objectTitle=歌礼丙肝新药ASC08二期临床试验数据发布, objectType=article, longId=48323, objectId=c6684832389, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6684832389, replyNumber=0, likeNumber=65, createdTime=2015-08-16, rootId=0, userName=ms24272190615788285182, userId=67e225929577, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6684832389, moduleTitle=歌礼丙肝新药ASC08二期临床试验数据发布, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c6684832389)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1665242, encodeId=f6c216652426d, content=<a href='/topic/show?id=3fac20931ac' target=_blank style='color:#2F92EE;'>#丙肝新药#</a>, objectTitle=艾伯维丙肝新药Viekira + Exviera获欧洲药品委员会批准, objectType=article, longId=45691, objectId=02a245691ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02a245691ef, replyNumber=0, likeNumber=60, createdTime=2015-06-12, rootId=0, userName=ms24272190615788285182, userId=67e225929577, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02a245691ef, moduleTitle=艾伯维丙肝新药Viekira + Exviera获欧洲药品委员会批准, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=02a245691ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1665241, encodeId=fd7c166524103, content=<a href='/topic/show?id=3fac20931ac' target=_blank style='color:#2F92EE;'>#丙肝新药#</a>, objectTitle=吉利德丙肝地位撼动——百时美丙肝新药Daklinza获欧盟批准——鸡尾酒治愈率达100%, objectType=article, longId=39744, objectId=afa239e4413, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=afa239e4413, replyNumber=0, likeNumber=62, createdTime=2015-05-05, rootId=0, userName=ms24272190615788285182, userId=67e225929577, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=afa239e4413, moduleTitle=吉利德丙肝地位撼动——百时美丙肝新药Daklinza获欧盟批准——鸡尾酒治愈率达100%, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=afa239e4413)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1665234, encodeId=f5a31665234f3, content=<a href='/topic/show?id=3fac20931ac' target=_blank style='color:#2F92EE;'>#丙肝新药#</a>, objectTitle=强生丙肝新药OLYSIO(simeprevir)获FDA批准, objectType=article, longId=27073, objectId=5ca32e07362, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ca32e07362, replyNumber=0, likeNumber=64, createdTime=2014-03-30, rootId=0, userName=ms24272190615788285182, userId=67e225929577, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ca32e07362, moduleTitle=强生丙肝新药OLYSIO(simeprevir)获FDA批准, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5ca32e07362)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1665238, encodeId=91271665238b5, content=<a href='/topic/show?id=3fac20931ac' target=_blank style='color:#2F92EE;'>#丙肝新药#</a>, objectTitle=吉利德提交丙肝新药Ledipasvir/Sofosbuvir新药申请, objectType=article, longId=30574, objectId=48d9305e40e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48d9305e40e, replyNumber=0, likeNumber=65, createdTime=2014-04-02, rootId=0, userName=ms24272190615788285182, userId=67e225929577, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48d9305e40e, moduleTitle=吉利德提交丙肝新药Ledipasvir/Sofosbuvir新药申请, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=48d9305e40e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1665240, encodeId=107a1665240e5, content=<a href='/topic/show?id=3fac20931ac' target=_blank style='color:#2F92EE;'>#丙肝新药#</a>, objectTitle=百时美向FDA提交丙肝新药NDA, objectType=article, longId=33002, objectId=badb33002f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=badb33002f3, replyNumber=0, likeNumber=72, createdTime=2014-04-10, rootId=0, userName=ms24272190615788285182, userId=67e225929577, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=badb33002f3, moduleTitle=百时美向FDA提交丙肝新药NDA, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=badb33002f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1665236, encodeId=9f721665236ea, content=<a href='/topic/show?id=3fac20931ac' target=_blank style='color:#2F92EE;'>#丙肝新药#</a>, objectTitle=吉利德丙肝新药Sovaldi获FDA批准, objectType=article, longId=27830, objectId=0bb52e8303b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0bb52e8303b, replyNumber=0, likeNumber=55, createdTime=2014-03-19, rootId=0, userName=ms24272190615788285182, userId=67e225929577, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0bb52e8303b, moduleTitle=吉利德丙肝新药Sovaldi获FDA批准, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0bb52e8303b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
风湿免疫小助手
关注
已关注
丙肝新药
2020-05-29
ms24272190615788285182
(审核中...)
关注
已关注
前往app查看评论内容
#丙肝新药#
【深度解读】医保谈判谁是很大赢家?PD-1谈判结果爆冷,进口丙肝新药平均降价85%!
91
0
2020-05-01
回复
ms24272190615788285182
(审核中...)
关注
已关注
前往app查看评论内容
#丙肝新药#
知名肝病专家王宇明:丙肝新药应尽快纳入医保
55
0
2019-10-10
回复
ms24272190615788285182
(审核中...)
关注
已关注
前往app查看评论内容
#丙肝新药#
国家卫健委调整基本药物目录,丙肝新药“丙通沙”将被纳入
66
0
2018-09-09
回复
ms24272190615788285182
(审核中...)
关注
已关注
前往app查看评论内容
#丙肝新药#
治疗仅需8周!丙肝新药获批
69
0
2019-02-07
回复
ms24272190615788285182
(审核中...)
关注
已关注
前往app查看评论内容
#丙肝新药#
祝贺!默沙东重磅丙肝新药择必达®在中国获批
58
0
2018-07-19
回复
ms24272190615788285182
(审核中...)
关注
已关注
前往app查看评论内容
#丙肝新药#
优先审评审批助力丙肝新药加快上市
77
0
2018-03-18
回复
ms24272190615788285182
(审核中...)
关注
已关注
前往app查看评论内容
#丙肝新药#
又有丙肝新药在国内获批上市了!
64
0
2018-08-12
回复
ms24272190615788285182
(审核中...)
关注
已关注
前往app查看评论内容
#丙肝新药#
3款重磅丙肝新药中国上市!
66
0
2018-07-09
回复
ms24272190615788285182
(审核中...)
关注
已关注
前往app查看评论内容
#丙肝新药#
4篇文章引发争议,丙肝新药或增加肝癌风险?
71
0
2016-12-16
回复
ms24272190615788285182
(审核中...)
关注
已关注
前往app查看评论内容
#丙肝新药#
FDA发布新指南:丙肝新药研发须开展“头对头”研究
61
0
2016-11-22
回复
ms24272190615788285182
(审核中...)
关注
已关注
前往app查看评论内容
#丙肝新药#
WHO更新基药目录 增抗丙肝新药等
88
0
2015-11-04
回复
ms24272190615788285182
(审核中...)
关注
已关注
前往app查看评论内容
#丙肝新药#
3型丙肝福音!百时美丙肝新药Daklinza获FDA批准
66
0
2016-02-23
回复
ms24272190615788285182
(审核中...)
关注
已关注
前往app查看评论内容
#丙肝新药#
AASLD 2015:丙肝新药Daklinza治疗晚期肝纤维化3型丙肝治愈率达100%
67
0
2016-10-16
回复
ms24272190615788285182
(审核中...)
关注
已关注
前往app查看评论内容
#丙肝新药#
歌礼丙肝新药ASC08二期临床试验数据发布
65
0
2015-08-16
回复
ms24272190615788285182
(审核中...)
关注
已关注
前往app查看评论内容
#丙肝新药#
艾伯维丙肝新药Viekira + Exviera获欧洲药品委员会批准
60
0
2015-06-12
回复
ms24272190615788285182
(审核中...)
关注
已关注
前往app查看评论内容
#丙肝新药#
吉利德丙肝地位撼动——百时美丙肝新药Daklinza获欧盟批准——鸡尾酒治愈率达100%
62
0
2015-05-05
回复
ms24272190615788285182
(审核中...)
关注
已关注
前往app查看评论内容
#丙肝新药#
强生丙肝新药OLYSIO(simeprevir)获FDA批准
64
0
2014-03-30
回复
ms24272190615788285182
(审核中...)
关注
已关注
前往app查看评论内容
#丙肝新药#
吉利德提交丙肝新药Ledipasvir/Sofosbuvir新药申请
65
0
2014-04-02
回复
ms24272190615788285182
(审核中...)
关注
已关注
前往app查看评论内容
#丙肝新药#
百时美向FDA提交丙肝新药NDA
72
0
2014-04-10
回复
ms24272190615788285182
(审核中...)
关注
已关注
前往app查看评论内容
#丙肝新药#
吉利德丙肝新药Sovaldi获FDA批准
55
0
2014-03-19
回复
共28条
首页
上一页
下一页
尾页
页码:
1
/2页
20条/页
扫描二维码下载梅斯医学APP
map
科室
订阅+
更多科室
工具
服务
map
map